In­cyte wins ac­cel­er­at­ed ap­proval for PD-1 in rare skin can­cer

In­cyte tout­ed an ac­cel­er­at­ed ap­proval for its PD-1 reti­fan­limab in a rare skin can­cer on Wednes­day, rough­ly a year and a half af­ter the drug suf­fered a re­jec­tion in squa­mous cell car­ci­no­ma of the anal canal (SCAC).

Reti­fan­limab, mar­ket­ed as Zynyz, was ap­proved for metasta­t­ic or re­cur­rent lo­cal­ly ad­vanced Merkel cell car­ci­no­ma (MCC), a fast-grow­ing skin can­cer typ­i­cal­ly char­ac­ter­ized by a sin­gle, pain­less nod­ule. It’s rough­ly 40 times rar­er than melanoma, ac­cord­ing to the non­prof­it Skin Can­cer Foun­da­tion — but in­ci­dence is grow­ing, par­tic­u­lar­ly among old­er adults, In­cyte said in its an­nounce­ment.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN